BiotechVortex™

Tonix Pharma teams up Columbia University in COVID-19

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

Thu July 16, 2020 9:00 AM|GlobeNewswire|About: TNXP

Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics

Potential for Human Monoclonal Antibody COVID-19 Therapeutics to be Developed as a Result of the Collaboration

NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP)

https://www.tonixpharma.com/

https://www.columbia.edu/

https://www.tonixpharma.com/pipeline/overview

https://seekingalpha.com/symbol/TNXP

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

Download PDF

Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics

Potential for Human Monoclonal Antibody COVID-19 Therapeutics to be Developed as a Result of the Collaboration

NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP

https://www.tonixpharma.com/news-events/press-releases/detail/1215/tonix-pharmaceuticals-announces-research-collaboration-to

Pipeline

Tonix Pharma teams up Columbia University in COVID-19

Free "LabXchange" Science Education Accelerator = By Amgen Foundation & Harvard's Faculty Of A / S

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

Free "LabXchange" Science Education Accelerator = By Amgen Foundation & Harvard's Faculty Of A / S

Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences

Wed January 22, 2020 9:00 AM|PR Newswire|About: AMGN

Purpose-Built to Address Educational Barriers With Personalized Instruction

Virtual Lab Simulations Help Students Develop the Science Skills Needed to Solve Tomorrow's Challenges

PR Newswire

THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Jan. 22, 2020 /PRNewswire/ -- The Amgen (AMGN) Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS)

Amgen
Biotech
Experience

Scientific Discovery for
the Classroom

https://www.amgeninspires.com/amgen-biotech-experience/

https://www.amgeninspires.com/

https://www.amgen.com/

http://www.fas.harvard.edu/

https://www.prnewswire.com/news-releases/free-labxchange-science-education-accelerator-launched-by-amgen-foundation-and-harvards-faculty-of-arts-and-sciences-300990930.html

Experience the interactive Multichannel News Release here:

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults

Thu January 23, 2020 10:00 AM|Business Wire|About: PFE

University of Louisville Named First Center of Excellence

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) announced today the launch of its Vaccines Division’s Centers of Excellence Network,

https://www.businesswire.com/news/home/20200123005146/en/

https://www.pfizer.com/news

https://www.pfizer.com/science/vaccines

Pfizer Inc. designates UofL first-of-its-kind Center of Excellence for epidemiological research By BETTY COFFMAN -JANUARY 23, 2020

mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

Koneksa Health Announces Study Publication Validating mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring

Fri January 24, 2020 12:37 PM|PR Newswire|About: MRKPR Newswire

NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Koneksa Health, the leader in developing and implementing patient-focused digital biomarkers for drug development, along with Merck & Co, Inc. (MRK)

https://www.prnewswire.com/news-releases/koneksa-health-announces-study-publication-validating-mhealth-technologies-in-early-stage-clinical-trial-safety-monitoring-300992910.html

https://www.koneksahealth.com/

Clinical Pharmacology & Therapeutics banner ARTICLE “In‐House” Data on the Outside – A Mobile Health Approach Qinlei Huang Tami Crumley Christina Walters Liesbeth Cluckers Ingeborg Heirman Radha Railkar Gaurav Bhatia Matthew Cantor Christopher Benko Elena S. Izmailova Sylvie Rottey S. Aubrey Stoch First published: 19 January 2020

M72/AS01E[3] tuberculosis disease (TB) vaccine

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

27 January 2020

GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development

The M72/AS01E tuberculosis vaccine candidate demonstrated in a phase IIb trial the potential to reduce active pulmonary TB by half in adults with latent TB infection.[1]
Developing a new vaccine against TB is a global health priority to accelerate progress toward ending the TB epidemic[2] and one of the United Nations Sustainable Development Goals.
The licensing agreement is a significant step forward to continue the development of the vaccine candidate for low-income countries with high TB burdens.

Issued: London, UK

Glaxo out-licenses TB vaccine candidate for potential use in developing countries

Jan. 27, 2020 9:37 AM ET|About: GlaxoSmithKline plc (GSK)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3534699-glaxo-out-licenses-tb-vaccine-candidate-for-potential-use-in-developing-countries

https://www.gatesmri.org/

https://www.gsk.com/en-gb/research-and-development/our-pipeline#CTA

investigational vaccine candidate M72/AS01E October 2018

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

Accenture and Google Cloud Collaborate to Help Life Sciences Companies Advance the Discovery, Development and Delivery of Innovative Therapies

Tue January 28, 2020 8:59 AM|Business Wire|About: ACN, GOOG, GOOGL

Accenture’s INTIENT platform on Google Cloud will enhance insights and collaboration in the life sciences market

NEW YORK & SUNNYDALE, Calif.--(BUSINESS WIRE)-- Accenture (ACN) and Google Cloud (NASDAQ:GOOG, GOOGL)

https://www.businesswire.com/news/home/20200128005285/en/

MAY 16, 2019

Accenture Introduces INTIENT™, an Innovative Platform to Advance the Discovery, Development and Delivery of Patient Treatments

NEW YORK; May 16, 2019 – Accenture (NYSE: ACN) today introduced INTIENT™, a technology platform that vastly improves the continuity and flow of data across life sciences enterprises, supporting the delivery of ground-breaking treatments for patients.

https://newsroom.accenture.com/news/accenture-introduces-intient-an-innovative-platform-to-advance-the-discovery-development-and-delivery-of-patient-treatments.htm

https://www.accenture.com/us-en

https://seekingalpha.com/symbol/ACN

Google Cloud Platform

https://cloud.google.com/gcp/?utm_source=google&utm_medium=cpc&utm_campaign=na-US-all-en-dr-skws-all-all-trial-b-dr-1008076&utm_content=text-ad-none-any-DEV_c-CRE_109860918967-ADGP_Hybrid+%7C+AW+SEM+%7C+SKWS+%7C+US+%7C+en+%7C+Multi+~+Cloud-KWID_43700009609890930-kwd-19383198255&utm_term=KW_%2Bcloud-ST_%2Bcloud&gclid=CjwKCAiA1L_xBRA2EiwAgcLKA_QCCBmyU0_XJCIJpWarEtMD6mjXvc143PHT8qZc5OWXHSeCUFDs0xoCn5gQAvD_BwE

ULY 25, 2018 Accenture and Google Cloud Launch Business Group to Deliver Intelligent Enterprise Solutions and Transform Customer Experiences Accenture recognized as a Google Cloud Partner Award Winner in consecutive years NEW YORK and MOUNTAIN VIEW, Calif.; July 25, 2018 – Accenture (NYSE: ACN)

SkinMedica®

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

SkinMedica®

Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership

Thu January 30, 2020 8:00 AM|PR Newswire|About: CNATPR Newswire

SAN DIEGO, Jan. 30, 2020 /PRNewswire/ -- Histogen Inc.,

https://www.prnewswire.com/news-releases/histogen-and-allergan-expand-cell-conditioned-media-ccm-skin-care-partnership-300995899.html

https://www.histogen.com/

https://www.conatuspharma.com/

Allergan expands partnership with Histogen

Jan. 30, 2020 11:03 AM ET|About: Allergan plc (AGN)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3536406-allergan-expands-partnership-histogen

https://seekingalpha.com/symbol/CNAT

https://seekingalpha.com/symbol/AGN

Experience The SkinMedica® Difference See how we leverage your skin's natural healing properties to transform from the inside out.

BiotechVortex™

The NextSeq 2000 Sequencing System

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics

Mon January 13, 2020 12:06 PM|Business Wire|About: ILMN

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (ILMN)

https://www.businesswire.com/news/home/20200113005753/en/

https://www.illumina.com/destination/tso500-novaseq.html?npclid=CjwKCAiAx_DwBRAfEiwA3vwZYlDcE_wXo9SJfwIOAx-x80Nq6roPVcj_C6g6PqWk5i2zinqmHYlDhhoCT_0QAvD_BwE&utm_source=google&utm_medium=cpc&utm_term=trusight%20oncology%20500&utm_campaign=TSO500

https://www.illumina.com/systems/sequencing-platforms/nextseq-1000-2000.html?scid=2020-269PR1964

https://www.illumina.com/informatics/biological-interpretation/variant-analysis/rare-variants.html

https://www.illumina.com/products/by-type/informatics-products/dragen-bio-it-platform.html

https://www.illumina.com/

Illumina and Roche Partner to Broaden Patient Access to Genomic Testing

Mon January 13, 2020 11:55 AM|Business Wire|About: ILMN

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (ILMN)

https://seekingalpha.com/pr/17747113-illumina-and-roche-partner-to-broaden-patient-access-to-genomic-testing

Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN)

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer

Mon January 13, 2020 4:20 PM|PR Newswire|About: AMGN

Collaborations With Guardant Health and QIAGEN Will Develop Blood- and Tissue-Based Companion Diagnostics For Investigational KRAS(G12C) Inhibitor AMG 510

KRAS G12C is Present in 13% of Non-Small Cell Lung Cancers With no Approved Targeted Treatments

PR Newswire

THOUSAND OAKS, Calif., Jan. 13, 2020 /PRNewswire/ -- Amgen (AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V.

https://www.amgen.com/

https://www.prnewswire.com/news-releases/amgen-announces-global-diagnostic-collaborations-to-expand-molecular-testing-for-patients-with-non-small-cell-lung-cancer-300986051.html

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer First Company Developing a KRAS(G12C) Inhibitor to Announce Multi-Platform Companion Diagnostics Collaborations With Guardant Health and QIAGEN Will Develop Blood- and Tissue-Based Companion Diagnostics For Investigational KRAS(G12C) Inhibitor AMG 510 KRAS G12C is Present in 13% of Non-Small Cell Lung Cancers With no Approved Targeted Treatments THOUSAND OAKS, Calif., Jan. 13, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN)

Insilico enters into research collaboration with Pfizer Inc.

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Insilico enters into research collaboration with Pfizer Inc.

Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets

Tue January 14, 2020 8:30 AM|PR Newswire|About: PFE

NEW YORK, Jan. 14, 2020 /PRNewswire/ -- Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (PFE)

https://insilico.com/

https://www.prnewswire.com/news-releases/insilico-enters-into-research-collaboration-with-pfizer-inc-to-explore-novel-data-and-artificial-intelligence-system-for-potential-therapeutic-targets-300986562.html

https://endpts.com/alex-zhavoronkov-follows-landmark-paper-with-37m-round-for-insilico-featuring-top-notch-china-vcs/

https://insilico.com/#rec41965165

https://finance.yahoo.com/news/insilico-medicine-secures-37m-series-010000860.html

AI Pharma Pipeline We developed a comprehensive drug discovery engine, which utilizes millions of samples and multiple data types to discover signatures of disease and identify the most promising targets for billions of molecules that already exist or can be generated de novo with the desired set of parameters.

IDA Ireland

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Insilico enters into research collaboration with Pfizer Inc.

IDA Ireland

Operations in Ireland

Pfizer has IDA-supported facilities at five sites in Ireland that employ 3,500 people. It is the largest pharmaceutical sector investor and employer. From an initial investment of €10 million in 1969, Pfizer's total investment in Ireland now stands at nearly €8 billion.

https://www.idaireland.com/how-we-help/case-studies/pfizer

GSK employs 1,450 people in Ireland and first established operations here in 1975. It has two manufacturing operations in Dungarvan and is the largest employer in the town with almost 700 staff; it has a third manufacturing operation, where it develops and produces a range of bulk pharmaceuticals, together with R&D and European Trading operations in Cork; and in Dublin there are Sales and Marketing functions.

https://www.idaireland.com/how-we-help/case-studies/gsk

In 1997, Takeda, the largest pharmaceutical company in Japan, established a Formulation Plant in Bray, Wicklow, for the manufacture of three of the company’s blockbuster drugs (Prevacid, Blopress and Actos). The establishment of this facility was paramount to Takeda’s strategy in responding to expanding growth in the European and US markets. This plant has significantly expanded its operation since inception and operates on a 24 hour/7 day basis.

https://www.idaireland.com/how-we-help/case-studies/takeda

Merck & Co., New Jersey is a global research-driven pharmaceutical company and is the fifth largest pharmaceutical company in the world. Outside North America it is known as MSD. MSD has 5 facilities supported by IDA with over 1,900 permanent jobs. It has invested over €2.2 billion in Ireland. It procures significant amounts of Irish-sourced raw materials and services.

WuXi Bio to acquire Bayer facility

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

Wed January 15, 2020 7:26 PM|PR Newswire|About: WXXWY

First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities
WuXi Biologics (WXXWY) will be the back-up manufacturer for Kovaltry™ of Bayer

SHANGHAI and LEVERKUSEN, Germany, Jan. 15, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK)

https://www.wuxibiologics.com/

https://www.prnewswire.com/news-releases/wuxi-biologics-and-bayer-enter-into-an-acquisition-agreement-on-a-drug-product-plant-in-germany-300987934.html

https://seekingalpha.com/symbol/WXXWY

WUXI BIOLOGICS AND BAYER ENTER INTO AN ACQUISITION AGREEMENT ON A DRUG PRODUCT PLANT IN GERMANY WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany 2020/01/16

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Thu January 16, 2020 8:00 AM|Business Wire|About: A

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) is collaborating with researchers at two UK universities

https://www.agilent.com/

https://www.sheffield.ac.uk/

https://www.manchester.ac.uk/

https://www.businesswire.com/news/home/20200116005137/en/

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

SANTA CLARA, Calif. , January 16, 2020

https://www.agilent.com/about/newsroom/presrel/2020/16jan-ca20002.html

Agilent Technologies (A) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow Jan. 15, 2020 6:10 PM ET | About: Agilent Technologies, Inc. (A)

BiotechVortex™

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology

Fri January 10, 2020 7:00 AM|GlobeNewswire

Amunix to receive $40 million in upfront payment and may receive up to $1.5 billion in development and sales milestones
Roche to utilize XTEN, Amunix’s clinically validated therapeutic half-life extension technology, to discover and develop novel therapeutics

MOUNTAIN VIEW, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”),

https://www.amunix.com/

PIPELINE

LogicBio Therapeutics Announces Collaboration with Takeda

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome

Fri January 10, 2020 7:00 AM|GlobeNewswire|About: LOGC

– LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome –

– The collaboration agreement grants Takeda (TKPHF) an exclusive option to negotiate an exclusive, worldwide license to LogicBio’s LB-301 program –

– Crigler-Najjar syndrome is the second indication to be pursued using GeneRide™ platform –

CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (LOGC),

https://www.embopress.org/doi/full/10.15252/emmm.201707601

https://www.logicbio.com/

https://seekingalpha.com/symbol/LOGC

Our goal is to transform the lives of patients with rare genetic disease. By intervening early, we believe we will be able to restore the function of aberrant genes before the patients experience irreversible declines in function.

Almirall and WuXi Biologics Sign Strategic Collaboration Agreement

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

Almirall and WuXi Biologics Sign Strategic Collaboration Agreement

Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

Thu January 9, 2020 1:11 PM|PR Newswire|About: WXXWY

- The agreement is another in a series of strategic partnerships in which Almirall reinforces its position as a leader in the promotion for skin healthcare

- This collaboration showcases the power and versatile applications of WuXiBody™ in multiple therapeutic areas, including the development of First-in-Class molecules in dermatology

PR Newswire

BARCELONA, Spain, Jan. 9, 2020 /PRNewswire/ -- Almirall, S.A. (LBTSF) (ALM) and WuXi Biologics (WXXWY) ("WuXi Bio") (2269.HK)

https://www.almirall.com/

https://seekingalpha.com/symbol/WXXWY

https://www.prnewswire.com/news-releases/almirall-and-wuxi-biologics-sign-strategic-collaboration-agreement-for-multiple-bispecific-antibodies-targeting-dermatology-diseases-300984520.html

https://www.wuxibiologics.com/

Our product portfolio.

Swiss Biotech Association

Janssen Expands Research & Development Presence with Major Investment in South San Francisco

Almirall and WuXi Biologics Sign Strategic Collaboration Agreement

Global Innovation Index 2019: Switzerland is the world’s most-innovative country

Wednesday, July 24, 2019 @ 12:00 am

Switzerland is the world’s most-innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the 2019 edition of the Global Innovation Index (GII), which also identifies regional leaders India, South Africa, Chile, Israel and Singapore, with China, Vietnam and Rwanda topping their income groups.

Switzerland is the world’s most innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the GII 2019. https://www.wipo.int/global_innovation_index/en/2019/index.html

Contact

Swiss Biotech Association
Stauffacherstrasse 16
8004 Zürich
T: +41 44 455 56 78
E-mail

Swiss Biotech Association - Recently updated member listings

Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal

Janssen Expands Research & Development Presence with Major Investment in South San Francisco

Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal

Fri January 10, 2020 7:00 AM|GlobeNewswire|About: SRNE

SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE)

https://seekingalpha.com/symbol/SRNE

https://sorrentotherapeutics.com/pipeline/

Pipeline

Janssen Expands Research & Development Presence with Major Investment in South San Francisco

Fri January 10, 2020 4:00 PM|Business Wire|About: JNJ

Investment delivers on overall strategy to expand pharmaceutical research and development footprint and enhance presence in critical innovation hotbed

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)

https://www.janssen.com/

https://www.jnj.com/

https://www.businesswire.com/news/home/20200110005545/en/

Janssen Expands Research & Development Presence with Major Investment in South San Francisco Jan 10, 2020 United States NEW BRUNSWICK, NJ, January 10, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen)

BiotechVortex™

Evotec And Bristol-Myers Squibb Expand iPSC Collaboration

Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy

Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

Evotec And Bristol-Myers Squibb Expand iPSC Collaboration

Tue January 7, 2020 1:40 AM|Accesswire|About: EVTCY

ADDING CELL TYPES SUPPORTS DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASES AND TRIGGERS US$ 6 M PAYMENT TO EVOTEC

HAMBURG, GERMANY / ACCESSWIRE / January 7, 2020 / Evotec SE (EVOTF) (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.

Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016

https://www.evotec.com/en

https://seekingalpha.com/symbol/EVTCY

Evotec And Bristol-Myers Squibb Expand iPSC Collaboration Tuesday, January 7, 2020 1:40 AM ADDING CELL TYPES SUPPORTS DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASES AND TRIGGERS US$ 6 M PAYMENT TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / January 7, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.

Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy

Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

Wed January 8, 2020 8:15 AM|Business Wire|About: AZN, VCYT

Agreement enabled by Veracyte (VCYT) acquisition of NanoString diagnostics assets for global expansion

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte (Nasdaq: VCYT)

https://www.businesswire.com/news/home/20200108005252/en/

https://www.veracyte.com/

https://www.acerta-pharma.com/

Veracyte collaborates with Acerta Pharma

Jan. 8, 2020 8:32 AM ET|About: Veracyte, Inc. (VCYT)|By: Mamta Mayani, SA News Editor

https://seekingalpha.com/news/3530376-veracyte-collaborates-acerta-pharma

Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs.

Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy

Wed January 8, 2020 5:19 PM|GlobeNewswire|About: MDT

Randomized Control Trial Results to be Presented at NANS Jan. 23-26 in Las Vegas; New, Proprietary Differential Target Multiplexed (DTM) Therapy Available on Medtronic Intellis Spinal Cord Stimulation Platform

DUBLIN, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)

https://clinicaltrials.gov/ct2/show/NCT03606187

https://www.medtronic.com/us-en/index.html

https://www.cmocro.com/company/Stimgenics%2C+LLC/index.html

Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy Randomized Control Trial Results to be Presented at NANS Jan. 23-26 in Las Vegas; New, Proprietary Differential Target Multiplexed (DTM) Therapy Available on Medtronic Intellis Spinal Cord Stimulation Platform DUBLIN, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT)

Antibodies 3BNC117 and 10-1074

Eli Lilly & Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab

Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy

Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University

Thu January 9, 2020 8:30 AM|Business Wire|About: GILD

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)

https://www.businesswire.com/news/home/20200109005277/en/

https://www.rockefeller.edu/#

January 09, 2020 Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 9, 2020-- Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.

Pfizer teams up with eFFECTOR Therapeutics in cancer

Eli Lilly & Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab

Pfizer teams up with eFFECTOR Therapeutics in cancer

Jan. 9, 2020 9:36 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor

https://effector.com/

https://seekingalpha.com/symbol/TXMD

Pfizer Joins With EFFECTOR To Develop Therapy For Treatment-refractory Cancers

CONTRIBUTORRTTNews.com RTTNewsPUBLISHEDJAN 9, 2020 8:35AM EST

https://www.nasdaq.com/articles/pfizer-joins-with-effector-to-develop-therapy-for-treatment-refractory-cancers-2020-01-09

PIPELINE of Selective Translation Regulators eFFECTOR retains global rights to all of its programs

Eli Lilly & Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab

Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab

Thu January 9, 2020 8:00 AM|PR Newswire|About: LLYPR Newswire

INDIANAPOLIS, Jan. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Strateos, Inc.

STRATEOS ELASTIC CHEMISTRY

Scalable, automated chemistry via the cloud.

https://www.strateos.com/elastic-chemistry/

https://strateos.com/

https://www.prnewswire.com/news-releases/eli-lilly-and-company-in-collaboration-with-strateos-inc-launch-remote-controlled-robotic-cloud-lab-300984067.html

Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab 01/09/2020 Download PDF Web-based platform provides broad access to the first-ever cloud laboratory to integrate automated biology and chemistry research capabilities in a closed-loop system that enables an accelerated design-make-test-analyze cycle INDIANAPOLIS, Jan. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Strateos, Inc.

BiotechVortex™

human CD38 antibody (TJ202/MOR202)

Pulmatrix = Kinase Inhibitor Licensing Agreement w/ Lung Cancer Initiative at Johnson & Johnson

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

Fri January 3, 2020 8:30 AM|PR Newswire

SHANGHAI, Jan. 3, 2020 /PRNewswire/ -- I-Mab Biopharma

https://www.prnewswire.com/news-releases/i-mab-biopharma-announces-dosing-of-first-patient-in-a-pivotal-phase-2-study-of-tj202mor202-in-multiple-myeloma-in-mainland-china-300980844.html

http://www.i-mabbiopharma.com/en/

http://www.i-mabbiopharma.com/en/Partnering.aspx#row2

Pipeline Strategy and Progress

Pulmatrix = Kinase Inhibitor Licensing Agreement w/ Lung Cancer Initiative at Johnson & Johnson

Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson

Thu January 2, 2020 8:51 AM|PR Newswire|About: PULM

LEXINGTON, Mass., Jan. 2, 2020 /PRNewswire/ -- Pulmatrix, Inc. (PULM) (NASDAQ: PULM)

https://www.prnewswire.com/news-releases/pulmatrix-announces-kinase-inhibitor-licensing-agreement-with-lung-cancer-initiative-at-johnson--johnson-300980456.html

http://www.pulmatrix.com/pipeline.html

PULMATRiX is developing transformational inhaled therapies for patients with pulmonary disease, both rare and common

Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

Pulmatrix = Kinase Inhibitor Licensing Agreement w/ Lung Cancer Initiative at Johnson & Johnson

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos

Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

Mon January 6, 2020 6:30 AM|Business Wire|About: MRK

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

https://www.businesswire.com/news/home/20200106005313/en/

https://www.taiho.co.jp/en/

https://astx.com/

https://www.otsuka.co.jp/en/

Merck Establishes Strategic Oncology Collaboration with Taiho and Astex Monday, January 6, 2020 6:30 am EST

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Thu July 25, 2019 3:00 AM|PR Newswire|About: VAR

HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Thu July 25, 2019 3:00 AM|PR Newswire|About: VAR

NEWS PROVIDED BY Varian Jul 25, 2019, 03:00 ET

PALO ALTO, Calif. and STOCKHOLM, July 25, 2019 /PRNewswire/ -- Varian (NYSE: VAR) announced that the Karolinska University Hospital Solna in Sweden is the first hospital in Scandinavia to deliver High Dose Rate (HDR) brachytherapy treatments using the new Bravos™ afterloader system

http://www.varian.com

https://seekingalpha.com/article/4277633-varian-medical-systems-inc-2019-q2-results-earnings-call-slides

https://www.varian.com/oncology/products/treatment-delivery/brachytherapy-afterloaders-applicators/bravos

https://www.prnewswire.com/news-releases/karolinska-university-hospital-solna-delivers-hdr-brachytherapy-cancer-treatments-with-varian-bravos-afterloader-system-300889555.html

Karolinska University Hospital is one of Europe’s premier health facilities. Together with the world-respected Karolinska Institutet, we lead in development and medical break-throughs.

https://www.karolinska.se/?splitoption=splitdecision

Karolinska University Hospital is one of Europe’s premier health facilities. Together with the world-respected Karolinska Institutet, we lead in development and medical break-throughs.

Infliximab biosimilar

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos

HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines

Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China

Mon January 6, 2020 7:00 AM|GlobeNewswire|About: SRNE

SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (SRNE) announced today that its partner Mabpharm (HK:2181)

https://sorrentotherapeutics.com/pipeline/

https://sorrentotherapeutics.com/

http://www.mabpharm.cn/en/index.php

Pipeline

HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos

HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines

HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry

Mon January 6, 2020 7:00 AM|GlobeNewswire|About: HOOK

NEW YORK and VIENNA, Austria, Jan. 06, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (HOOK)

https://www.hookipapharma.com/

https://www.hookipapharma.com/our-programs/our-pipeline/

Our goal is to transform the prevention and treatment of infectious diseases and cancers to significantly improve the lives of patients by developing and commercializing a new class of ‘‘off-the-shelf’’ immunotherapeutics. We are leveraging our modular arenavirus platform to develop the following product candidates for multiple infectious diseases and cancers - the efficacy of our TheraT®* and VaxWave®* platforms is being tested all across our pipeline:

BiotechVortex™

AZD7325, a novel α2/3–subtype-selective GABA A positive allosteric modulator (“PAM”)

BioInvent Announces Selection of Second Target and Extension of the Collaboration w/ Pfizer

AZD7325, a novel α2/3–subtype-selective GABA A positive allosteric modulator (“PAM”)

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

Mon December 23, 2019 8:30 AM|GlobeNewswire|About: AZN, FBIOGlobeNewswire

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”) today announced that Baergic Bio, Inc.

https://www.fortressbiotech.com/programs

Fortress Bio in-licenses rights for AstraZeneca's AZD7325

Dec. 23, 2019 8:52 AM ET|About: AstraZeneca PLC (AZN)|By: Mamta Mayani, SA News Editor

https://seekingalpha.com/news/3528108-fortress-bio-in-licenses-rights-for-astrazenecas-azd7325

AZD7325 Mechanism of action: Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAAα2,3) positive modulator

THERAVANCE BIOPHARMA AND PFIZER INC. ENTER GLOBAL LICENSE AGREEMENT

BioInvent Announces Selection of Second Target and Extension of the Collaboration w/ Pfizer

AZD7325, a novel α2/3–subtype-selective GABA A positive allosteric modulator (“PAM”)

Pfizer licenses Theravance's JAK inhibitors for skin conditions

Dec. 23, 2019 8:52 AM ET|About: Theravance Biopharma, Inc. (TBPH)|By: Liz Kiesche, SA News Editor

https://seekingalpha.com/symbol/TBPH

https://www.theravance.com/our-pipeline

THERAVANCE BIOPHARMA AND PFIZER INC. ENTER GLOBAL LICENSE AGREEMENT FOR SKIN-TARGETED, LOCALLY-ACTING PAN-JANUS KINASE (JAK) INHIBITOR PROGRAM Topically-Applied, Skin-Selective Pan-JAK Inhibitors Specifically Designed to Target Pro-Inflammatory Pathways with Minimal Systemic Exposure Monday, December 23, 2019 - 10:22am EST DUBLIN, IRELAND AND NEW YORK – December 23, 2019 – Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Pfizer Inc. (NYSE: PFE) (“Pfizer”)

BioInvent Announces Selection of Second Target and Extension of the Collaboration w/ Pfizer

BioInvent Announces Selection of Second Target and Extension of the Research Collaboration and License Agreement With Pfizer Inc.

Mon December 23, 2019 4:23 AM|PR Newswire|About: PFE

LUND, Sweden, Dec. 23, 2019 /PRNewswire/ -- BioInvent International AB ("BioInvent (BOVNF)" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. (PFE) ("Pfizer") (NYSE: PFE)

https://seekingalpha.com/symbol/BOVNF

https://www.prnewswire.com/news-releases/bioinvent-announces-selection-of-second-target-and-extension-of-the-research-collaboration-and-license-agreement-with-pfizer-inc-300978838.html

BioInvent announces selection of first target discovered by BioInvent’s proprietary F.I.R.S.T™ technology platform under collaboration with Pfizer Inc. Lund, Sweden – July 31, 2019 – BioInvent International AB (“BioInvent” or the “Company”) (OMXS: BINV) today announces that Pfizer Inc. (“Pfizer”) (NYSE: PFE) has selected the first target under the companies’ cancer immunotherapy research collaboration and license agreement, into which the companies entered in December 2016 to develop antibodies targeting tumor-associated myeloid cells.

Gilead & Eisai Enter Into Agreement in Japan for the Rheumatoid Arthritis Therapy Filgotinib

BioInvent Announces Selection of Second Target and Extension of the Collaboration w/ Pfizer

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

Tue December 24, 2019 1:00 AM|Business Wire|About: GILD

-- Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn’s Disease and Psoriatic Arthritis --

FOSTER CITY, Calif. & TOKYO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Eisai Co., Ltd. (Tokyo, Japan)

https://www.gilead.com/news-and-press/press-room/press-releases/2019/12/gilead-and-eisai-enter-into-agreement-in-japan-for-the-copromotion-of-the-investigational-rheumatoid-arthritis-therapy-filgotinib-pending-regulatory

https://www.businesswire.com/news/home/20191223005626/en/

Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb)

Gilead & Eisai Enter Into Agreement in Japan for the Rheumatoid Arthritis Therapy Filgotinib

Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.

Mon December 30, 2019 4:05 PM|PR Newswire|About: JNJ

HORSHAM, Pa., Dec. 30, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)

https://www.janssen.com/

https://www.prnewswire.com/news-releases/janssen-announces-completion-of-acquisition-of-investigational-bermekimab-from-xbiotech-inc-300979941.html

XBiotech is committed to advancing its robust pipeline of potential breakthrough antibody therapies. Each of the Company’s targeted antibody candidates were discovered and developed using XBiotech’s proprietary True Human™ technology.

http://www.xbiotech.com/clinical/index.php

XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen

http://investors.xbiotech.com/news-releases/news-release-details/xbiotech-closes-sale-true-human-antibody-bermekimab-janssen

Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.

Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

Gilead & Eisai Enter Into Agreement in Japan for the Rheumatoid Arthritis Therapy Filgotinib

Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

Thu January 2, 2020 8:15 AM|PR Newswire|About: AMGNPR Newswire

THOUSAND OAKS, Calif., Jan. 2, 2020 /PRNewswire/ -- Amgen (AMGN)

https://www.prnewswire.com/news-releases/amgen-commences-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china-300980441.html

https://seekingalpha.com/pr/17737857-beigene-announces-closing-of-amgen-global-strategic-oncology-collaboration-and-equity

BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment January 2, 2020 at 8:15 AM EST Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene Shares Anthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors CAMBRIDGE, Mass. and BEIJING, China, Jan. 02, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160)

BiotechVortex™

Medtronic and ChristianaCare Collaborate

Alexion = Two Additional GalXC™ RNAi Programs -Mediated Targets = Collaboration w/ Dicerna™

Medtronic and ChristianaCare Collaborate to Improve Patient Outcomes and Reduce Cost of Care in Delaware

Mon December 16, 2019 8:00 AM|GlobeNewswire|About: MDT

Value-Based Healthcare Collaboration Designed to Help ChristianaCare
Apply Right Therapies to Patients Who May Benefit Most

DUBLIN and NEW CASTLE, Del., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) and ChristianaCare

https://www.medtronic.com/us-en/index.html

ChristianaCare

https://christianacare.org/

Medtronic and ChristianaCare Collaborate to Improve Patient Outcomes and Reduce Cost of Care in Delaware Value-Based Healthcare Collaboration Designed to Help ChristianaCare Apply Right Therapies to Patients Who May Benefit Most DUBLIN and NEW CASTLE, Del., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) and ChristianaCare

Alexion = Two Additional GalXC™ RNAi Programs -Mediated Targets = Collaboration w/ Dicerna™

Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™

Mon December 16, 2019 8:00 AM|Business Wire|About: ALXN, DRNA

– Option Exercise Triggers $20 Million Payment to Dicerna –

BOSTON & LEXINGTON, Mass.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN) (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA)

https://www.businesswire.com/news/home/20191216005150/en/

https://alexion.com/

https://alexion.com/research-development/pipeline

https://dicerna.com/

Pipeline Developing next-generation RNAi therapies.

BAN2401 is an investigational humanized monoclonal antibody

Alexion = Two Additional GalXC™ RNAi Programs -Mediated Targets = Collaboration w/ Dicerna™

BAN2401 is an investigational humanized monoclonal antibody

BioArctic Announces Research Collaboration with Eisai Regarding BAN2401

Tue December 17, 2019 10:21 AM|PR Newswire|About: B, BIOA

STOCKHOLM, Dec. 17, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)

https://www.prnewswire.com/news-releases/bioarctic-announces-research-collaboration-with-eisai-regarding-ban2401-300976162.html

A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD)

https://clinicaltrials.gov/ct2/show/NCT03887455

BAN2401 – Alzheimer’s disease In Alzheimer’s disease soluble, toxic amyloid beta aggregates are believed to contribute to the neurodegenerative process. BAN2401, a humanized monoclonal antibody, selectively binds to these forms of amyloid beta and eliminates them. The antibody’s unique profile is highly selective for amyloid beta oligomers/protofibrils in the brain. BioArctic’s belief is that BAN2401’s unique binding profile is important and differentiates it from other antibodies.

Leronlimab

Arcus Biosciences, in Collaboration with Genentech

BAN2401 is an investigational humanized monoclonal antibody

CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV

Tue December 17, 2019 4:36 PM|GlobeNewswire|About: CYDY

In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn (CYDY) of $4 million in the form of registered CytoDyn common stock

CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications

VANCOUVER, Washington and NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc., (“CytoDyn”) and Vyera Pharmaceuticals, LLC (“Vyera”)

https://www.cytodyn.com/

https://www.cytodyn.com/pipeline/hiv

https://www.vyera.com/

CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV December 17, 2019 4:36pm EST

Stealth Autoguide™ System

Arcus Biosciences, in Collaboration with Genentech

Medtronic Expands Surgical Synergy(SM) with FDA Clearance of the Stealth Autoguide™ System for Cranial Procedures

Wed December 18, 2019 7:00 AM|GlobeNewswire|About: MDT

Robotic Trajectory Guidance Platform Integrates Multiple Enabling Technologies to Support Complex Cranial Procedures

DUBLIN, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)

https://www.medtronic.com/us-en/index.html

The StealthStation™ S8 surgical navigation system has an intuitive interface, improved patient registration software, and advanced visualization to navigate neurosurgery procedures. The system offers optical and Electromagnetic (EM) tracking capabilities, and integrates with external devices like microscopes, ultrasound, and a broad array of Medtronic instruments. Explore the capabilities, applications, and technology of this powerful surgical technology.

Arcus Biosciences, in Collaboration with Genentech

Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers

Wed December 18, 2019 4:05 PM|Business Wire|About: RCUS

Collaboration leverages Genentech’s MORPHEUS studies to accelerate development of AB928, a potential best-in-class therapy targeting the adenosine axis to stimulate immune responses against cancer

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (RCUS)

https://www.arcusbio.com/

https://www.businesswire.com/news/home/20191218005727/en/

Arcus Bio to collaborate with Roche on two cancer studies

Dec. 18, 2019 4:23 PM ET|About: Arcus Biosciences, Inc. (RCUS)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3527252-arcus-bio-to-collaborate-roche-on-two-cancer-studies

PIPELINE

BiotechVortex™

200,000 Ebola vaccine regimens to the Republic of Rwanda

Invitae launches Discover Dysplasias program for skeletal dysplasias

ImmunOs Therapeutics AG, BioMedPartners and Pfizer Ventures

Johnson & Johnson Announces Commitment to Support Republic of Rwanda's Preparedness Against Ebola Outbreak

Sun December 8, 2019 8:00 AM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., Dec. 8, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ)

https://www.prnewswire.com/news-releases/johnson--johnson-announces-commitment-to-support-republic-of-rwandas-preparedness-against-ebola-outbreak-300971018.html

https://www.eccmidlive.org/#

https://www.janssen.com/infectious-diseases-and-vaccines

https://www.who.int/immunization/policy/position_papers/interim_ebola_recommendations_may_2019.pdf?ua=1

https://www.jnj.com/innovation/the-race-to-create-an-ebola-vaccine

Combating Ebola: How a Johnson & Johnson Vaccine Is Helping in the Fight The company has committed to donate up to 500,000 doses of an investigational Janssen vaccine regimen to help protect citizens of the Democratic Republic of the Congo—the site of the world's second largest outbreak of the disease.

ImmunOs Therapeutics AG, BioMedPartners and Pfizer Ventures

Invitae launches Discover Dysplasias program for skeletal dysplasias

ImmunOs Therapeutics AG, BioMedPartners and Pfizer Ventures

ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials

Tue December 10, 2019 3:00 AM|Business Wire|About: PFE

SCHLIEREN, Switzerland--(BUSINESS WIRE)-- ImmunOs Therapeutics AG, a Swiss bio-technology company

http://www.immunostherapeutics.com/

https://www.businesswire.com/news/home/20191210005042/en/

At ImmunOs Therapeutics AG, we have discovered a novel family class of therapeutics to explore ways to stimulate the innate immune system and increase the efficacy of checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancers (e.g. Pancreatic, Colon, Melanoma, Lymphoma, and Breast). Our products differentiate from the common competitor antibodies, as we not only target a single receptor (as antibodies do) but target diverse receptors using one molecule to create a synergistic response between immune cells that activate anti-tumor responses. We also explore the combination of our products with diverse types of cancer therapies, such as chemotherapy, vaccines, etc.

Invitae launches Discover Dysplasias program for skeletal dysplasias

Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias

Tue December 10, 2019 7:30 AM|PR Newswire|About: NVTAPR Newswire

SAN FRANCISCO, Dec. 10, 2019 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA)

https://www.invitae.com/en/

https://www.biomarin.com/discoverdysplasias/

https://www.prnewswire.com/news-releases/invitae-announces-program-with-biomarin-to-expand-access-to-genetic-testing-for-skeletal-dysplasias-300971840.html

https://www.invitae.com/en/sponsored-testing/

https://www.biomarin.com/products/pipeline

Discover Dysplasias™ provides no‐charge genetic testing for patients suspected of having a skeletal dysplasia. Discover Dysplasias™ can help facilitate diagnosis and, in some cases, put patients on the path to disease‐specific management sooner1,2

Kevzara® (sarilumab) and Praluent® (alirocumab)

Merck to Acquire ArQule, Advancing Leadership in Oncology

Invitae launches Discover Dysplasias program for skeletal dysplasias

Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

Tue December 10, 2019 8:30 AM|GlobeNewswire|About: SNY

Sanofi (SNY) and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

December 10, 2019 at 8:29 AM EST Back

REGENERON AND SANOFI ANNOUNCE INTENT TO RESTRUCTURE ANTIBODY COLLABORATION FOR KEVZARA® (SARILUMAB) AND PRALUENT® (ALIROCUMAB)

TARRYTOWN, N.Y. and PARIS, Dec. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi

https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-intent-restructure-antibody

Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body's most complex mysteries.

Merck to Acquire ArQule, Advancing Leadership in Oncology

Mon December 9, 2019 6:45 AM|Business Wire|About: ARQL, MRK

Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies

KENILWORTH, N.J. & BURLINGTON, Mass.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (ARQL)

https://www.businesswire.com/news/home/20191209005234/en/

Merck to Acquire ArQule, Advancing Leadership in Oncology Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies Monday, December 9, 2019 6:45 am EST

Takeda Partners with MiTest Health

Merck to Acquire ArQule, Advancing Leadership in Oncology

Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn's Disease Management

Fri December 13, 2019 3:05 PM|PR Newswire|About: TAKPR Newswire

LEXINGTON, Mass., Dec. 13, 2019 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A. (TSE: 4502) (NYSE:TAK) ("Takeda (TKPHF)") and MiTest Health LLC

https://www.prnewswire.com/news-releases/takeda-partners-with-mitest-health-to-launch-innovative-disease-risk-prediction-tool-to-redefine-crohns-disease-management-300974776.html

Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn's Disease Management PR Newswire PR NewswireDecember 13, 2019

BiotechVortex™

Neurocrine Biosciences & Xenon Pharmaceuticals Announce Agreement to Develop Treatments for Epilepsy

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Mon December 2, 2019 7:30 AM|PR Newswire|About: NBIX, XENE

Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All Licensed Products, as well as Option to Co-Fund XEN901

PR Newswire

SAN DIEGO and BURNABY, British Columbia, Dec. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and Xenon Pharmaceuticals Inc. (XENE)

https://www.xenon-pharma.com/product-pipeline/

https://www.neurocrine.com/pipeline/pipeline-overview/

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy 12/02/19 PDF Version Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All Licensed Products, as well as Option to Co-Fund XEN901 SAN DIEGO and BURNABY, British Columbia, Dec. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy.

Seattle Genetics & Astellas team up with Merck in first-line urothelial cancer

Neurocrine Biosciences & Xenon Pharmaceuticals Announce Agreement to Develop Treatments for Epilepsy

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

- Companies to Initiate Phase 3 Trial to Support Global Registrations -

https://www.businesswire.com/news/home/20191202005357/en/

https://www.seattlegenetics.com/

https://www.astellas.com/en/

Enfortumab vedotin is an antibody-drug conjugate (ADC) composed of an anti-Nectin-4 monoclonal antibody attached to our synthetic cell-killing agent, monomethyl auristatin E (MMAE), a microtubule-disrupting agent, using our proprietary linker technology. Enfortumab vedotin is the first agent to target Nectin-4, which is expressed on many solid tumors, with especially uniform expression on bladder cancers. Preclinical studies showed that enfortumab vedotin effectively binds to target cells, internalizes and induces cell-killing activity. We are co-developing enfortumab vedotin with Astellas.

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)

Neurocrine Biosciences & Xenon Pharmaceuticals Announce Agreement to Develop Treatments for Epilepsy

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)

FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

Mon December 2, 2019 7:00 AM|GlobeNewswire|About: FGEN

SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN)

https://www.fibrogen.com/

FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN)

https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-roxadustat-inclusion-chinas-national

https://seekingalpha.com/news/3522929-fibrogen-3-percent-reimbursement-roxadustat-china

Redefining How to Treat Anemia in Chronic Kidney Disease We are advancing roxadustat, our first-in-class, oral small molecule product candidate for the treatment of anemia associated with chronic kidney disease (CKD), through global Phase 3 clinical development. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI),

Reblozyl® (luspatercept-aamt)

Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)

Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes

Tue December 3, 2019 7:38 AM|Business Wire|About: BMY, XLRN

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) (NYSE: BMY) and Acceleron Pharma Inc. (XLRN)

https://media.celgene.com/content/uploads/reblozyl-pi.pdf

https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-acceleron-pharma-announce-fda-advisor

http://acceleronpharma.com/science-pipeline/pipeline/

https://www.businesswire.com/news/home/20191203005566/en/

https://seekingalpha.com/news/3523331-fda-ad-com-set-for-bristol-myers-luspatercept-for-mds

http://acceleronpharma.com/

Pipeline

Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts

Wed December 4, 2019 8:30 AM|PR NewswirePR Newswire

LEXINGTON, Mass., Dec. 4, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc.,

https://www.prnewswire.com/news-releases/thermo-fisher-scientific-opens-90-million-viral-vector-manufacturing-site-in-massachusetts-300968837.html

https://www.thermofisher.com/us/en/home.html

https://seekingalpha.com/news/3523641-thermo-fisher-cuts-ribbon-on-new-90m-viral-vector-manufacturing-site

Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts New facility will create 200 new jobs and accelerate commercialization of gene and cell therapies LEXINGTON, Mass., Dec. 4, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc.

NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte

Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts

NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte

Tue December 3, 2019 5:00 PM|Business Wire|About: NSTG

Creates Potential for Significantly Expanded Test Menu

Sharpens NanoString’s Strategic Focus on Rapidly Growing Research Business Including Recent Launch of GeoMx Digital Spatial Profiler

Strengthens Financial Profile through Capital Infusion and Streamlined Operations

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NSTG

https://www.businesswire.com/news/home/20191203006031/en/

https://www.nanostring.com/

https://seekingalpha.com/news/3523662-nanostring-announces-exclusive-license-of-ncounter-diagnostic-assets-to-veracyte

https://www.veracyte.com/

VERACYTE ACQUIRES EXCLUSIVE LICENSE TO NANOSTRING DIAGNOSTICS PLATFORM, POSITIONING VERACYTE TO EXPAND ITS GENOMIC TESTING BUSINESS GLOBALLY Dec 3, 2019 Strategic transaction enables Veracyte to access global markets through a world-class, distributed instrument system, with an initial focus on its pulmonology franchise Provides pathway for long-term revenue growth and margin expansion Veracyte to hold conference call and webcast today at 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 3, 2019-- Veracyte (Nasdaq: VCYT

BiotechVortex™

Moderna (MRNA) & Harvard University

Dragonfly Therapeutics Announces Collaboration with AbbVie

Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University

September 26, 2019 at 8:00 AM EDTPDF Version

Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2019-- Moderna, Inc., (Nasdaq: MRNA)

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-mrna-immunotherapy-research-collaboration

September 26, 2019

Harvard University establishes mRNA immunotherapy research collaboration with Moderna

Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities

Cambridge, Mass. - September 26, 2019 — Harvard University

https://otd.harvard.edu/news/harvard-university-establishes-mrna-immunotherapy-research-collaboration-wi

Moderna collaborates with Harvard University for immunology programs

Sep. 26, 2019 8:42 AM ET|About: Moderna, Inc. (MRNA)|By: Mamta Mayani, SA News Editor

https://seekingalpha.com/news/3502018-moderna-collaborates-harvard-university-immunology-programs

https://www.modernatx.com/pipeline

Dragonfly Therapeutics Announces Collaboration with AbbVie

Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

Wed November 20, 2019 8:00 AM|PR Newswire|About: ABBV

Dragonfly will use its TriNKET™ platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology. AbbVie receives exclusive options to license a number of Dragonfly's natural killer (NK) cell engager immunotherapies.

WALTHAM, Mass., Nov. 20, 2019 /PRNewswire/ -- Dragonfly Therapeutics

https://www.dragonflytx.com/

https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-collaboration-with-abbvie-for-autoimmune-diseases-and-oncology-300961954.html

https://www.dragonflytx.com/about-us

We Use NK Cells to Kill Cancer At Dragonfly we invent therapies that harness the body's immune system, for vastly improved patient outcomes.

Bristol-Myers Squibb Completes Acquisition of Celgene

Dragonfly Therapeutics Announces Collaboration with AbbVie

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration

Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company

Wed November 20, 2019 4:16 PM|Business Wire|About: AMGN, BMY, CELG

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) announced today that it has completed its acquisition of Celgene Corporation (CELG)

https://www.businesswire.com/news/home/20191120005929/en/

https://seekingalpha.com/news/3521028-bristol-myers-finalizes-celgene-buy

Bristol-Myers Squibb Completes Acquisition of Celgene
Creating a Leading Biopharma Company

https://bestofbiopharma.com/

Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company CATEGORY: CORPORATE/FINANCIAL NEWS WEDNESDAY, NOVEMBER 20, 2019 4:16 PM EST NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

Thu November 21, 2019 4:00 AM|GlobeNewswire|About: ABBV, HARP

SOUTH SAN FRANCISCO, Calif. and NORTH CHICAGO, Ill., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc. (ABBV)

https://www.globenewswire.com/NewsRoom/AttachmentNg/7e618bf2-6d57-40b3-bdd8-00765a1ed497

https://www.harpoontx.com/pipeline/

https://news.abbvie.com/news/press-releases/harpoon-therapeutics-and-abbvie-announce-licensing-and-option-collaboration-to-advance-hpn217-harpoons-bcma-targeting-tritac-and-expand-existing-discovery-collaboration.htm

HARPOON THERAPEUTICS AND ABBVIE ANNOUNCE LICENSING AND OPTION COLLABORATION TO ADVANCE HPN217, HARPOON’S BCMA-TARGETING TRITAC®, AND EXPAND EXISTING DISCOVERY COLLABORATION Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration includes up to six additional targets selected by AbbVie Two agreements provide for a total of $50 million in upfront and up to $50 million in a contingent milestone payment for first patient treated with HPN217 in a clinical trial SOUTH SAN FRANCISCO, Calif. and NORTH CHICAGO, Ill., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc. (NYSE: ABBV)

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration

WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Fri November 22, 2019 2:30 AM|Business Wire|About: ZYME

SINGAPORE--(BUSINESS WIRE)-- Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics

https://www.businesswire.com/news/home/20191121005148/en/

Zymeworks reports updated ZW25 Phase 1 data in HER2-expressing cancers

Nov. 22, 2019 7:08 AM ET|About: Zymeworks Inc. (ZYME)|By: Mamta Mayani, SA News Editor

https://seekingalpha.com/news/3521477-zymeworks-reports-updated-zw25-phase-1-data-her2-expressing-cancers

We currently have two wholly-owned product candidates in clinical development and several wholly-owned product candidates in preclinical development that leverage our multiple therapeutic platforms to address areas of significant unmet medical need.

WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration

WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

Fri November 22, 2019 12:15 PM|PR Newswire|About: WXXWY

DUNDALK, Ireland, Nov. 22, 2019 /PRNewswire/ -- WuXi Biologics (WXXWY) ("WuXi Bio") (2269.HK)

https://www.prnewswire.com/news-releases/wuxi-vaccines-to-build-a-240-million-manufacturing-facility-in-ireland-300963906.html

https://www.wuxibiologics.com/

https://seekingalpha.com/news/3521626-wuxi-vaccines-build-240m-manufacturing-facility-ireland

WuXi Vaccines investment to bring 200 additional jobs to Dundalk

https://www.idaireland.com/newsroom/wuxi-vaccines-investment-to-bring-200-jobs-dundalk

https://www.wuxibiologics.com/services-solutions/drug-product-cgmp-gmp-fill-finish/

https://www.wuxibiologics.com/

WuXi Vaccines investment to bring 200 additional jobs to Dundalk November 22nd, 2019 – Dundalk. Minister for Business, Enterprise & Innovation Heather Humphreys TD

BiotechVortex™

Bristol-Myers Squibb and Pfizer

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4B

Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals

Fri November 15, 2019 9:00 AM|Business Wire|About: PFE

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- The Bristol-Myers Squibb-Pfizer Alliance

https://www.businesswire.com/news/home/20191115005062/en/

https://my.clevelandclinic.org/health/articles/13398-know-your-risk-factors-for-stroke

BRISTOL-MYERS SQUIBB AND PFIZER ANNOUNCE RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECT OF ATRIAL FIBRILLATION SCREENING ON HEALTH OUTCOMES IN OLDER INDIVIDUALS Friday, November 15, 2019 - 9:00am EST PRINCETON, N.J. & The Bristol-Myers Squibb-Pfizer Alliance

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4B

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

Mon August 26, 2019 6:30 AM|Business Wire|About: AMGN, BMY, CELG

Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger

Pending Bristol-Myers Squibb-Celgene Merger Expected to Close by End of 2019

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) announced today that Celgene Corporation (CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (AMGN) under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash.

https://www.businesswire.com/news/home/20190826005247/en/

https://seekingalpha.com/news/3519945-ftc-board-bristol-myers-celgene-tie-otezla-sale

Otezla® (apremilast) is a prescription medicine approved for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is a prescription medicine approved for the treatment of adult patients with active psoriatic arthritis. Otezla is a prescription medicine approved for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4B

Vertex and Molecular Templates Establish Collaboration

Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

Mon November 18, 2019 6:00 AM|Business Wire|About: DRNA

– Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates –

– Each Company to Retain Rights to Co-Develop and

Co-Commercialize Product Candidates –

– Dicerna to Receive Upfront Payment of USD 175 Million and

Equity Investment of USD 50 Million –

– Dicerna is Eligible to Receive an Additional USD 75 Million Over the First Three Years, Plus Up to USD 357.5 Million per Target in Potential Milestone Payments, and Royalties on Product Sales –

– Dicerna to Host Conference Call Today at 8:00 a.m. ET –

LEXINGTON, Mass., & BAGSVÆRD, Denmark--(BUSINESS WIRE)-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) and Novo Nordisk A/S

https://dicerna.com/

https://www.businesswire.com/news/home/20191118005269/en/

novonordisk.com

18 Nov 2019 12:01 CET Dicerna and Novo Nordisk enter agreement to discover and develop RNAi therapies for liver-related cardio-metabolic diseases Collaboration to explore liver cell targets using Dicerna’s GalXC™ technology with the potential to deliver a significant number of clinical candidates Each company to retain rights to co-develop and co-commercialise product candidates Dicerna to receive upfront payment of USD 175 million and equity investment of USD 50 million Dicerna is eligible to receive an additional USD 75 million over the first three years, plus up to USD 357.5 million per target in potential milestone payments, and royalties on product sales Lexington, Massachusetts, US, and Bagsværd, Denmark, 18 November 2019 – Dicerna™ Pharmaceuticals, Inc. and Novo Nordisk A/S

Vertex and Molecular Templates Establish Collaboration

Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

Mon November 18, 2019 7:00 AM|GlobeNewswire|About: MTEM

-Molecular Templates (MTEM) to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales-

BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc.

https://mtem.com/

https://www.vrtx.com/

https://mtem.com/etb-platform/pipeline/

Nov 18, 2019 Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”)

Varian ProBeam Compact Proton Therapy System

Vertex and Molecular Templates Establish Collaboration

Varian ProBeam Compact Proton Therapy System

First Cancer Patient Treated with Varian ProBeam Compact Proton Therapy System at Treatment Center in Florida

Mon November 18, 2019 8:15 AM|PR Newswire|About: VAR

PALO ALTO, Calif., Nov. 18, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR)

https://www.varian.com/

https://www.prnewswire.com/news-releases/first-cancer-patient-treated-with-varian-probeam-compact-proton-therapy-system-at-treatment-center-in-florida-300959639.html

Proton Therapy The use of proton therapy to treat cancerous tumors is a major technological advance. Proton therapy delivers the beam precisely where it is required. After decades of development, its success is rapidly driving proton therapy out of research facilities and into regional treatment centers worldwide. Thanks to increasingly sophisticated imaging, delivery and scanning techniques, the options for treatment by proton therapy continue to expand.

ORION-10 Study of Inclisiran

Vertex and Molecular Templates Establish Collaboration

Varian ProBeam Compact Proton Therapy System

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

Sat November 16, 2019 10:45 AM|Business Wire|About: MDCO

- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD)

- ORION-10 study affirmed inclisiran’s excellent safety profile, including no treatment-related liver or renal abnormalities

- Results presented today during late-breaking science session at American Heart Association annual meeting in Philadelphia

- The Medicines Company (MDCO) to host investor conference call and webcast on Monday, November 18, 12:00 pm EST

PHILADELPHIA--(BUSINESS WIRE)

https://www.themedicinescompany.com/

https://seekingalpha.com/news/3520048-medicines-company-2-percent-premarket-positive-inclisiran-data

Clinical Development ORION clinical development program At The Medicines Company, we are devoted to the development of inclisiran – a small interfering RNA (siRNA) therapy being studied to evaluate its ability to lower low-density lipoprotein (LDL) cholesterol – also known as LDL-C or bad cholesterol. Inclisiran is designed to prevent the production of proprotein convertase subtilisin/kexin type 9 (PCSK9) at its primary source in the liver. Inclisiran is not yet approved for use by the FDA or any other regulatory authority.

BiotechVortex™

Editas Medicine and Celgene Corporation

Celgene inks second collaboration deal with Skyhawk

Editas Medicine and Celgene Corporation

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

Tue November 12, 2019 7:00 AM|GlobeNewswire|About: EDIT

The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells

Editas Medicine (EDIT) to receive a $70 million payment and may be eligible for future milestone and royalty payments

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced an amended collaboration with Celgene Corporation (Nasdaq: CELG)

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells Editas Medicine to receive a $70 million payment and may be eligible for future milestone and royalty payments CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced an amended collaboration with Celgene Corporation (Nasdaq: CELG)

CABOMETYX® (cabozantinib)

Celgene inks second collaboration deal with Skyhawk

Editas Medicine and Celgene Corporation

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

Tue November 12, 2019 8:02 AM|Business Wire|About: EXEL

– Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (NASDAQ:EXEL)

https://www.businesswire.com/news/home/20191112005303/en/

https://ir.exelixis.com/news-releases/news-release-details/exelixis-partner-ipsen-announces-health-canadas-approval-0

https://www.ipsen.com/partnering/

https://www.exelixis.com/

What is CABOMETYX? CABOMETYX is a prescription medicine used to treat people with: Advanced kidney cancer (renal cell carcinoma) Liver cancer (hepatocellular carcinoma) who have been previously treated with the medicine sorafenib.

Celgene inks second collaboration deal with Skyhawk

Exicure (NASDAQ:XCUR) will collaborate with Allergan (NYSE:AGN)

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Tue November 12, 2019 9:00 AM|PR Newswire|About: CELG

Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets.

Skyhawk to receive $80 Million upfront payment and is eligible for potential milestone payments and royalties.

WALTHAM, Mass., Nov. 12, 2019 /PRNewswire/ -- Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered into a second global strategic collaboration with an affiliate of Celgene Corporation (CELG)

https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-a-second-multi-target-collaboration-agreement-with-celgene-to-discover-and-develop-novel-small-molecules-that-modulate-rna-splicing-300956283.html

At Skyhawk Therapeutics we use proprietary structural, kinetic, and computational models to invent small molecules that correct splicing in RNA, targeting some of the world's most intractable diseases

Exicure (NASDAQ:XCUR) will collaborate with Allergan (NYSE:AGN)

SAREPTA AND STRIDEBIO ANNOUNCE MULTI-TARGET STRATEGIC COLLABORATION

Exicure (NASDAQ:XCUR) will collaborate with Allergan (NYSE:AGN)

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

Thu November 14, 2019 7:00 AM|Business Wire|About: AGN, XCUR

- Exicure (XCUR) to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones

- Exicure to Host Conference Call Today at 8:30am ET/7:30am CT

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc., (NASDAQ:XCUR)

https://www.businesswire.com/news/home/20191114005106/en/

https://seekingalpha.com/news/3519164-exicure-teams-allergan-hair-loss-disorders-shares-24-percent-premarket

Allergan is focused on driving innovation in four core therapeutic areas. As part of our approach to delivering innovation for better patient care, we have built one of the broadest pharmaceutical and device research and development pipelines in the industry.

https://www.allergan.com/research-and-development/pipeline

EXICURE PIPELINE Exicure has a broad pipeline of SNA-based therapeutics to treat a range of diseases with great unmet medical need. The unique properties of the SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types

SAREPTA AND STRIDEBIO ANNOUNCE MULTI-TARGET STRATEGIC COLLABORATION

Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies

Thu November 14, 2019 8:30 AM|GlobeNewswire|About: SRPT

CAMBRIDGE, Mass. and RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (SRPT),

14 NOV SAREPTA AND STRIDEBIO ANNOUNCE MULTI-TARGET STRATEGIC COLLABORATION TO ADVANCE NOVEL GENE THERAPIES Posted at 13:28h in Uncategorized by admin Agreement leverages StrideBio’s novel, industry-leading, structure-driven capsid engineering platform and expands Sarepta’s early stage gene therapy pipeline Sarepta granted an exclusive license to four CNS targets, on which StrideBio will lead early research and development inclusive of IND-enabling capsid and construct development Sarepta granted an exclusive option for four additional neuromuscular and CNS targets Cambridge, Mass., and Research Triangle Park, N.C., Nov. 14., 2019 – Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

ETRASIMOD

SAREPTA AND STRIDEBIO ANNOUNCE MULTI-TARGET STRATEGIC COLLABORATION

Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia

Thu November 14, 2019 9:00 AM|GlobeNewswire|About: ARNA

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE)

https://www.arenapharm.com/

http://www.everestmedicines.com/index.html

Drug Candidate for Treatment of Immune-Mediated and Inflammatory Diseases Etrasimod is a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena, and designed for optimized pharmacology and engagement of S1P receptor 1, 4 and 5 which may lead to an improved efficacy and safety profile. Etrasimod provides systemic and local effects on specific immune cell types and has the potential to treat multiple immune-mediated inflammatory diseases including ulcerative colitis, Crohn’s disease, and atopic dermatitis. Etrasimod is an investigational compound that is not approved for any use in any country.

BiotechVortex™

New Global R&D Centre, AI Innovation Centre and a joint investment fund with CICC

Antengene Corporation today announced it has a licensing agreement with AstraZeneca (LSE/STO/ AZN

Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.

AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development

PUBLISHED6 November 2019

New Global R&D Centre, AI Innovation Centre and a joint investment fund with CICC to underpin next phase of growth and support transformation of healthcare in China

https://seekingalpha.com/news/3515077-astrazeneca-launches-1b-china-investment-fund

CICC To Provide Comprehensive Financial Service and Technical Support As China’s first joint venture investment bank, China International Capital Corporation Limited (CICC) has always been committed to providing high quality value-added financial services for clients. CICC has established a full-service investment bank business framework based on its research foundation for the development of investment banking, equities, FICC, wealth management and investment management.

Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.

Antengene Corporation today announced it has a licensing agreement with AstraZeneca (LSE/STO/ AZN

Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

Wed November 6, 2019 7:30 AM|GlobeNewswire|About: BIIB

Biogen to gain exclusive commercialization rights to two new ophthalmology biosimilars referencing Lucentis and Eylea in the U.S., Canada, Europe, Japan and Australia
Will provide Biogen with commercialization rights for its current anti-TNF biosimilars portfolio in China, adding to its strategic presence in this priority market
Includes an option to extend the term of its existing European commercial agreement

CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.

https://www.samsungbioepis.com/en/index.do

https://investors.biogen.com/news-releases/news-release-details/biogen-expand-biosimilars-portfolio-and-gain-access-additional

06/11/2019 Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates • Agreement with Biogen covers Samsung Bioepis’ biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept • Includes an option for Biogen to extend existing commercialization agreement for Samsung Bioepis’ anti-TNF medicines in Europe – BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) – which have treated over 180,000 patients across Europe i • Samsung Bioepis continues its commitment to increasing patient access to high-quality medicines, by expanding its efforts to ophthalmology, in addition to immunology, oncology, and hematology INCHEON, Korea – November 06, 2019 – Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia. SB11, a biosimilar candidate referencing LUCENTIS®ii (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing EYLEA®iii (aflibercept), is in pre-clinical development.

Antengene Corporation today announced it has a licensing agreement with AstraZeneca (LSE/STO/ AZN

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

Wed November 6, 2019 11:31 AM|PR Newswire|About: AZN, CELG

SHANGHAI and LONDON, Nov. 6, 2019 /PRNewswire/ -- Antengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (AZNCF) (LSE/STO/NYSE: AZN)

https://www.prnewswire.com/news-releases/antengene-corporation-announces-exclusive-worldwide-license-to-develop-and-commercialize-azd0364-300953003.html

Antengene's pipeline includes five clinical-stage products, ranging from Phase 1/2 to NDA stage. ATG-010 is a first-in-class selective inhibitor of nuclear export. It is approved for treatment of relapsed/refractory multiple myeloma in the U.S., and there are multiple registration studies ongoing for additional indications including diffuse large B-cell lymphoma, liposarcoma, endometrial cancer, etc.

University of Vermont Health Network begins offering Genomic DNA Testing

Galectin Therapeutics Reaches Agreement w Siemens Healthineers - Collaborate on NASH &Liver Fibrosis

Antengene Corporation today announced it has a licensing agreement with AstraZeneca (LSE/STO/ AZN

University of Vermont Health Network begins offering Genomic DNA Testing

Fri November 8, 2019 5:59 PM|PR Newswire|About: NVTA

https://www.prnewswire.com/news-releases/university-of-vermont-health-network-begins-offering-genomic-dna-testing-300955047.html

University of Vermont Health Network begins offering Genomic DNA Testing Pilot project holds promise for helping inform Vermonters’ health care decisions BURLINGTON – The University of Vermont Health Network

Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab

Galectin Therapeutics Reaches Agreement w Siemens Healthineers - Collaborate on NASH &Liver Fibrosis

Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting

Fri November 8, 2019 4:05 PM|GlobeNewswire|About: ADROQ3: 11-07-19 Earnings SummaryEPS of $-0.26 misses by $-0.02 Revenue of $4.8M (56.68% Y/Y) beats by $0.76M

BERKELEY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,

(see www.clinicaltrials.gov, identifier NCT03396445).

https://investors.aduro.com/news-releases/news-release-details/aduro-biotech-announces-presentation-results-first-human-phase-1?field_nir_news_date_value[min]=2019

Aduro’s extensive pipeline of diverse product candidates builds from proprietary technologies (STING and APRIL Pathway) to create immunotherapies targeting a variety of diseases including cancer, autoimmune and infectious disease.

Galectin Therapeutics Reaches Agreement w Siemens Healthineers - Collaborate on NASH &Liver Fibrosis

Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

Mon November 11, 2019 9:47 AM|GlobeNewswire|About: GALT

NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic steatohepatitis (NASH) and liver fibrosis.

https://clinicaltrials.gov/ct2/show/NCT02462967?lead=galectin&phase=12&draw=2&rank=1

https://galectintherapeutics.com/

Pipeline

BiotechVortex™

AMGN, BGNE

Gilead Sciences, Inc. (GILD) Galapagos NV (GLPGF)

BeiGene Announces Global Strategic Oncology Collaboration with Amgen

Thu October 31, 2019 4:00 PM|GlobeNewswire|About: AMGN, BGNE

• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China

• Companies to Jointly Develop 20 Amgen (AMGN) Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in China as Part of the Global Development Plan

• Amgen to Purchase Approximately $2.7 Billion of BeiGene Shares

• BeiGene to Hold Analyst and Investor Call on Thursday, October 31 at 8:00 p.m. ET

CAMBRIDGE, Mass. and BEIJING, China, Oct. 31, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE) and Amgen

https://www.beigene.com/science-and-product-portfolio/pipeline

https://www.amgen.com/media/news-releases/2019/10/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/

https://seekingalpha.com/news/3512709-amgen-teams-beigene-cancer

Amgen (AMGN) Announces Collaboration with BeiGene - Slideshow

Nov. 11, 2019 1:30 PM ET | About: Amgen Inc. (AMGN)

https://seekingalpha.com/article/4305471-amgen-amgn-announces-collaboration-beigene-slideshow

BeiGene Announces Global Strategic Oncology Collaboration with Amgen October 31, 2019 at 4:00 PM EDT • Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China • Companies to Jointly Develop 20 Amgen Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in China as Part of the Global Development Plan • Amgen to Purchase Approximately $2.7 Billion of BeiGene Shares • BeiGene to Hold Analyst and Investor Call on Thursday, October 31 at 8:00 p.m. ET CAMBRIDGE, Mass. and BEIJING, China, Oct. 31, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and Amgen (NASDAQ: AMGN)

Gilead Sciences, Inc. (GILD) Galapagos NV (GLPGF)

Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

Fri November 1, 2019 4:01 PM|GlobeNewswire|About: GLPG

Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ: GILD), delivered an exercise notice to Galapagos NV (GLPGF) (Euronext & NASDAQ: GLPG)

https://seekingalpha.com/news/3513251-gilead-stake-galapagos-25_1-percent

Clinical Pipeline Galapagos is progressing one of the largest pipelines in biotech, with a broad range of disease areas being explored in Phase 2 and Phase 3 with filgotinib, Phase 3 with '1690 and Phase 2 with '1205 in IPF, multiple Phase 1 and Phase 2 studies with other clinical programs, and >20 discovery programs.

SYK

Gilead Sciences, Inc. (GILD) Galapagos NV (GLPGF)

cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies

Stryker announces definitive agreement to acquire Wright Medical

Mon November 4, 2019 7:00 AM|GlobeNewswire|About: SYK

Kalamazoo, Michigan, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Stryker (SYK)

https://www.stryker.com/

Stryker

cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies

Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

Tue November 5, 2019 7:00 AM|Business Wire|About: TAK

− Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021

− Potential to be the First CAR Cell Therapy Approved for Outpatient Administration

HOUSTON & OSAKA, Japan--(BUSINESS WIRE)-- The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK) (“Takeda”)

https://www.businesswire.com/news/home/20191105005250/en/

https://www.takeda.com/

https://www.mdanderson.org/cancermoonshots/cancer-types/Leukemia_CLL.html

https://www.mdanderson.org/cancermoonshots/cancer-types/b-cell-lymphoma.html

https://www.mdanderson.org/cancermoonshots/research_platforms/adoptive-cell-therapy.html

https://www.mdanderson.org/

Stem Cell Transplantation & Cellular Therapy

BeiGene (BGNE) and Seattle Genetics (SGEN) to Collaborate

cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies

BeiGene (BGNE) and Seattle Genetics (SGEN) to Collaborate

Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

Tue November 5, 2019 8:00 AM|Business Wire|About: BGNE, SGEN

https://www.businesswire.com/news/home/20191105005417/en/

https://www.seattlegenetics.com/pipeline

https://www.beigene.com/science-and-product-portfolio/pipeline

Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate November 5, 2019 at 8:00 AM EST -BeiGene and Seattle Genetics to Collaborate on Global Clinical Trials- BOTHELL, Wash. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE

Libtayo® (cemiplimab)

cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies

BeiGene (BGNE) and Seattle Genetics (SGEN) to Collaborate

Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer

TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

https://seekingalpha.com/pr/17686221-regeneron-provides-updates-phase-3-libtayo-cemiplimab-development-program-advanced-non-small

https://www.regeneron.com/libtayo-injection

https://www.libtayo.com/

LIBTAYO is a prescription medicine used to treat people with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that: has spread –or– cannot be cured by surgery or radiation

BiotechVortex™

WALGREENS, SUSAN G. KOMEN AND LLS COLLABORATE TO SUPPORT RESEARCH

CNP-101/TAK-101, immune modifying nanoparticle to induce tolerance to gluten in patients with celiac

WALGREENS, SUSAN G. KOMEN AND LLS COLLABORATE TO SUPPORT RESEARCH

Walgreens, Susan G. Komen and The Leukemia & Lymphoma Society Collaborate to Support Research in Tough-to-Treat Cancers and Increase Access to Care

Tue October 22, 2019 9:00 AM|Business Wire|About: WBA

$25M, multi-year commitment builds on Walgreens (WBA) efforts to improve the health and well-being of people living with cancer nationwide

DEERFIELD, Ill. & DALLAS & RYE BROOK, N.Y.--(BUSINESS WIRE)-- Walgreens announced today a new collaboration with Susan G. Komen and The Leukemia & Lymphoma Society

https://www.businesswire.com/news/home/20191022005311/en/

https://www.lls.org/lls-us-hq/news/walgreens-susan-g-komen-and-lls-collaborate-to-support-research-in-tough-to-treat-cancers-and-increase-access-to-care?news=News%20Releases&newsid=12355

https://ww5.komen.org/

WALGREENS, SUSAN G. KOMEN AND LLS COLLABORATE TO SUPPORT RESEARCH $25M, multi-year commitment builds on Walgreens efforts to improve the health and well-being of people living with cancer nationwide

Abbott's Alinity s Solution

CNP-101/TAK-101, immune modifying nanoparticle to induce tolerance to gluten in patients with celiac

WALGREENS, SUSAN G. KOMEN AND LLS COLLABORATE TO SUPPORT RESEARCH

The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening

Mon October 21, 2019 9:00 AM|PR Newswire|About: ABT PR Newswire

ABBOTT PARK, Ill., Oct. 21, 2019 /PRNewswire/ -- Abbott (ABT)

https://www.prnewswire.com/news-releases/the-australian-red-cross-blood-service-selects-abbotts-alinity-s-solution-for-blood-and-plasma-screening-300941474.html

UNLOCK NEW POTENTIAL WITH Alinity s PURPOSE-BUILT FOR BLOOD AND PLASMA SCREENING.

CNP-101/TAK-101, immune modifying nanoparticle to induce tolerance to gluten in patients with celiac

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Tue October 22, 2019 1:00 AM|Business Wire|About: TAK

− Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease

− Takeda (TKPHF) acquires exclusive global license to investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease

OSAKA, Japan & CHICAGO--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”)

https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes

https://www.takeda.com/newsroom/newsreleases/2019/takeda-acquires-license-for-first-in-class-celiac-disease-therapy-from--cour-pharmaceuticals-following-positive-phase-2a-proof-of-concept-study/

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study − Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease − Takeda acquires exclusive global license to investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease

QuantiFERON®-TB Gold Plus (QFT®-Plus)

ABBV will advance= potentiator into clinical development for use in treatments cystic fibrosis (CF)

CNP-101/TAK-101, immune modifying nanoparticle to induce tolerance to gluten in patients with celiac

QIAGEN’s QuantiFERON®-TB Gold Plus Test Added to the Global Drug Facility Catalog for Public Health Efforts

Tue October 29, 2019 5:05 PM|Business Wire|About: QGEN

QIAGEN expands market for gold standard latent TB test to help developing countries fight TB
WHO-endorsed test to support communities with the highest need
First demonstration of QuantiFERON®-TB Access at the Union World meeting in India

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN)

https://www.businesswire.com/news/home/20191029005850/en/

https://www.who.int/tb/publications/global_report/en/

http://www.stoptb.org/gdf/

QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts as well as up-to-date licensing information and product-specific disclaimers can be found at www.quantiferon.com/us. The performance of the USA format of the QFT-Plus test has not been extensively evaluated with specimens from individuals younger than age 17 years.

ABBV will advance= potentiator into clinical development for use in treatments cystic fibrosis (CF)

AbbVie Announces Collaboration with Cystic Fibrosis Foundation

Thu October 24, 2019 8:00 AM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill., Oct. 24, 2019 /PRNewswire/ -- AbbVie (ABBV)

https://www.prnewswire.com/news-releases/abbvie-announces-collaboration-with-cystic-fibrosis-foundation-300944388.html

THE CF FOUNDATION LAB DEVOTES MORE THAN HALF OF ITS EFFORTS TO RESEARCH FOCUSED ON NONSENSE AND OTHER RARE MUTATIONS.

Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT

ABBV will advance= potentiator into clinical development for use in treatments cystic fibrosis (CF)

Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT

Wed October 30, 2019 6:59 AM|Business Wire|About: BMY

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) (NYSE:BMY) and LabCentral

https://www.businesswire.com/news/home/20191030005268/en/

https://www.carminetherapeutics.com/

A LAUNCHPAD FOR HIGH‑POTENTIAL LIFE‑SCIENCES STARTUPS.

BiotechVortex™

ILMN, QGEN

Valiant® TAAA Stent Graft System

ILMN, QGEN

Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Mon October 7, 2019 4:05 PM|Business Wire|About: ILMN, QGEN

Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making

SAN DIEGO & HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- Illumina, Inc. (ILMN) and QIAGEN N.V. (QGEN)

Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making October 07, 2019 04:05 PM Eastern Daylight Time SAN DIEGO & HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA)

Valiant® TAAA Stent Graft System

ILMN, QGEN

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence

October 1, 2019 | Microsoft News Center

Multiyear alliance underpins the Novartis commitment to leverage data & artificial intelligence (AI) to transform how medicines are discovered, developed and commercialized
Novartis to establish AI innovation lab to empower its associates to use AI across the business
Joint research activities will include co-working environments on Novartis Campus (Switzerland), at Novartis Global Service Center in Dublin, and at Microsoft Research Lab (UK) – starting with tackling personalized therapies for macular degeneration; cell & gene therapy; and drug design

Basel, and Redmond, October 1, 2019

Valiant® TAAA Stent Graft System

Medtronic Receives FDA Breakthrough Device Designation for Developing Stent Graft System to Treat Thoracoabdominal Aortic Aneurysm

Tue October 8, 2019 10:00 AM|GlobeNewswire|About: MDTGlobeNewswire

DUBLIN, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)

Select the Valiant Navion™ thoracic stent graft system for your thoracic endovascular aortic repair (TEVAR) procedures. The low-profile delivery system with FreeFlo and CoveredSeal proximal stent graft options are designed for versatility, uncompromising conformability, control, and accuracy. The reimagined design offers enhanced vascular access with a broad set of options to treat a wide range of patient anatomies.

BLUE NVO

Abbott (ABT) and Tandem Diabetes Care (TNDM)

Valiant® TAAA Stent Graft System

bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

Wed October 9, 2019 8:00 AM|Business Wire|About: BLUE

CAMBRIDGE, Mass. and BAGSVÆRD, Denmark--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO)

bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases October 09, 2019 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass. and BAGSVÆRD, Denmark--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO)

Abbott (ABT) and Tandem Diabetes Care (TNDM)

Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management

Tue October 15, 2019 8:00 AM|PR Newswire|About: ABT, TNDMPR Newswire

ABBOTT PARK, Ill. and SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Abbott (ABT) and Tandem Diabetes Care (TNDM)

Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management - Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes ABBOTT PARK, Ill. and SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Tandem Diabetes Care (NASDAQ: TNDM)

Living With Diabetes

Abbott (ABT) and Tandem Diabetes Care (TNDM)

Roche Partners with iHeartMedia to Present 'iHeartCountry One Night For Our Military' Concert to Bring Further Awareness of The Impact Diabetes Has On The Nation's Veteran Population

Mon October 14, 2019 8:00 AM|PR Newswire|About: CHGCY, IHRT, RHHBY

-- Event Will Broadcast Nationwide On Veteran's Day From The Country Music Hall of Fame, Honoring The One In Four Veterans Living With Diabetes In The U.S.

PR Newswire

INDIANAPOLIS, Oct. 14, 2019 /PRNewswire/ -- Roche (ROCM) (SIX: RO, ROG; OTCQX: RHHBY)

https://www.prnewswire.com/news-releases/roche-partners-with-iheartmedia-to-present-iheartcountry-one-night-for-our-military-concert-to-bring-further-awareness-of-the-impact-diabetes-has-on-the-nations-veteran-population-300937249.html

https://www.research.va.gov/pubs/docs/va_factsheets/Diabetes.pdf

About Roche Diagnostics Roche is the world's largest biotech company, focuses on improving people's lives. Roche Diagnostics is a leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a frontrunner in diabetes management. Headquartered in Indianapolis, Indiana, Roche Diagnostics employees over 4,500 people who enjoy a site identity that reflects, "A welcoming community where heart and innovation come together."

BiotechVortex™

Pfizer (PFE)

T-Cell Receptor Engineered T-cell Therapy (TCR-T) programs

Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina

Wed August 21, 2019 10:00 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- Pfizer (PFE)

PFIZER INVESTS HALF BILLION DOLLARS TO ADVANCE STATE-OF-THE-ART GENE THERAPY FACILITY IN SANFORD, NORTH CAROLINA Wednesday, August 21, 2019 - 10:00am EDT

T-Cell Receptor Engineered T-cell Therapy (TCR-T) programs

Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies

Aug 28, 2019 | News, USA

Celgene Secures Exclusive Options to Three Immatics TCR-T Targets
Immatics to Receive $75 Million Upfront Payment and May Be Eligible for Future Opt-in Exercise, Milestone and Royalty
Immatics Retains Options to Co-Develop or Co-Fund Certain Licensed Products

Houston, Texas and Tuebingen, Germany, August 28, 2019 – Immatics Biotechnologies GmbH

Celgene teams up with Immatics in cancer immunotherapies Aug. 28, 2019 7:47 AM ET|About: Celgene Corporation (CELG)|By: Douglas W. House, SA News Editor

CIVO™ multiplexed intratumoral microdosing platform,

T-Cell Receptor Engineered T-cell Therapy (TCR-T) programs

smart insulin pens into Continuous Glucose Monitoring (CGM) devices

Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology

Tue August 27, 2019 8:00 AM|PR Newswire|About: BMY

SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences

Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology NEWS PROVIDED BY Presage Biosciences Aug 27, 2019, 08:00 ET

smart insulin pens into Continuous Glucose Monitoring (CGM) devices

AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR

smart insulin pens into Continuous Glucose Monitoring (CGM) devices

Medtronic and Novo Nordisk Enter Agreement to Provide Integrated Digital Solutions for People with Diabetes

Mon September 16, 2019 3:00 AM|GlobeNewswire|About: MDTGlobeNewswire

DUBLIN and BAGSVÆRD, Denmark, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) (NYSE:MDT), and Novo Nordisk A/S

STARTING PUMP THERAPY

AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR

Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

Mon September 9, 2019 7:30 AM|Business Wire|About: ALXN, BBIO, EIDX

- Eidos grants Alexion (ALXN) exclusive license to develop and commercialize AG10 in Japan -

- Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 -

- Agreement expands Alexion’s amyloidosis portfolio -

- Eidos to receive upfront payment of $25 million and equity investment of $25 million, with potential for additional Japanese-based milestone- & royalty-dependent payments -

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and BridgeBio Pharma, Inc. (BBIO)’s (NASDAQ:BBIO) subsidiary Eidos Therapeutics, Inc. (EIDX) (NASDAQ:EIDX)

the pipeline

FreeStyle Libre technology with Sanofi′s insulin dosing information for future smart pens,

AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR

ABBOTT AND SANOFI PARTNER TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES TO HELP CHANGE THE WAY DIABETES IS MANAGED

- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin

- Two world leaders in diabetes work together to drive meaningful change in care

ABBOTT PARK, Ill. and PARIS, Sept. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Sanofi

anofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin Two world leaders in diabetes work together to drive meaningful change in care PARIS and ABBOTT PARK, ILL. – September 16, 2019 – Sanofi and Abbott

BiotechVortex™

Innovation-Lounge with focus on diabetes

iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps

Lilly Germany kicks off Innovation-Lounge with focus on diabetes

by LillyPad 30/07/2019

By Dr. Stefanie Beck, Government Affairs Manager Lilly Germany.

Lilly current products include: By Therapeutic

iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps

LILLY, EVIDATION HEALTH AND APPLE STUDY SHOWS PERSONAL DIGITAL DEVICES MAY HELP IN THE IDENTIFICATION OF MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER'S DISEASE DEMENTIA

Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia

08/08/2019Download PDF

INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL)

https://seekingalpha.com/pr/17597726-lilly-evidation-health-apple-study-shows-personal-digital-devices-may-help-identification

New ways to measure health in everyday life.

Optune® Tumor Treating Fields

iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps

Financial Time - Novartis (NVS) to file 50 applications for drug approvals in China by 2023

China National Medical Products Administration Grants I

seeking biotech alpha is biotecMAX 生物技术最大 6/2/2023 the heart of biotech

BiotechVortex™

Tonix Pharma teams up Columbia University in COVID-19

Tonix Pharma teams up Columbia University in COVID-19

Tonix Pharma teams up Columbia University in COVID-19

Tonix Pharma teams up Columbia University in COVID-19

Tonix Pharma teams up Columbia University in COVID-19

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

Tonix Pharma teams up Columbia University in COVID-19

Free "LabXchange" Science Education Accelerator = By Amgen Foundation & Harvard's Faculty Of A / S

Free "LabXchange" Science Education Accelerator = By Amgen Foundation & Harvard's Faculty Of A / S

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

Free "LabXchange" Science Education Accelerator = By Amgen Foundation & Harvard's Faculty Of A / S

Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences

Purpose-Built to Address Educational Barriers With Personalized Instruction

Virtual Lab Simulations Help Students Develop the Science Skills Needed to Solve Tomorrow's Challenges

Amgen Biotech Experience

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults

mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

PFE Vaccines Launches Global Network to Conduct Real-World Research on Vaccine-Preventable Diseases

Koneksa Health Announces Study Publication Validating mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring

M72/AS01E[3] tuberculosis disease (TB) vaccine

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development

Glaxo out-licenses TB vaccine candidate for potential use in developing countries

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

Accenture and Google Cloud Collaborate to Help Life Sciences Companies Advance the Discovery, Development and Delivery of Innovative Therapies

Google Cloud Platform

SkinMedica®

Accenture and Google Cloud Collaborate to Help Life Sciences Companies

SkinMedica®

Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership

Allergan expands partnership with Histogen

BiotechVortex™

The NextSeq 2000 Sequencing System

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics

Illumina and Roche Partner to Broaden Patient Access to Genomic Testing

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer

Collaborations With Guardant Health and QIAGEN Will Develop Blood- and Tissue-Based Companion Diagnostics For Investigational KRAS(G12C) Inhibitor AMG 510

KRAS G12C is Present in 13% of Non-Small Cell Lung Cancers With no Approved Targeted Treatments

Insilico enters into research collaboration with Pfizer Inc.

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

Insilico enters into research collaboration with Pfizer Inc.

Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets

IDA Ireland

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Insilico enters into research collaboration with Pfizer Inc.

IDA Ireland

Operations in Ireland

WuXi Bio to acquire Bayer facility

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

BiotechVortex™

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology

LogicBio Therapeutics Announces Collaboration with Takeda

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome

Amgen
Biotech
Experience